Management of renal osteodystrophy in CKD includes which of the following?

• A. Phosphate binders to reduce phosphate absorption and vitamin D analogs to manage hypocalcemia
• B. Increasing phosphate intake and avoiding calcium supplements
• C. Restrictive protein diet alone, no mineral binder
• D. High-dose calcium-free phosphate supplements

Answer: (A)

In CKD, renal osteodystrophy arises from disturbances in phosphate, calcium, and vitamin D leading to secondary hyperparathyroidism and bone turnover problems. The best management combines lowering the phosphate load and correcting calcium and vitamin D status. Phosphate binders, taken with meals, bind dietary phosphate in the gut and reduce its absorption, helping to prevent hyperphosphatemia that drives hypocalcemia and excess PTH. Vitamin D analogs activate vitamin D receptors, increase calcium absorption from the gut, and directly suppress parathyroid hormone, addressing both hypocalcemia and secondary hyperparathyroidism. Using these together targets the core abnormalities that drive bone changes in CKD.

Increasing phosphate intake or avoiding calcium supplements would worsen phosphate balance and bone health. Relying on protein restriction alone without mineral binders doesn’t control phosphate or PTH, and using calcium-free phosphate supplements would not correct the underlying imbalance and could worsen phosphate load.